Englewood Lab (A950140) Q3 2025 earnings summary

Executive summary

• Operates as a cosmetics ODM/OEM manufacturer in the US, specializing in skincare and functional cosmetics, with a strong R&D focus and global certifications.

• Main revenue comes from moisturizers, face creams, SPF, acne, BB, and foundation products, with 68.2% of sales from basic skincare.

• Maintains a single consolidated subsidiary in Korea, fully owned, and listed on KOSDAQ since 2016.

Financial highlights

• 9M 2025 consolidated revenue: $114.86M, down from $133.59M YoY; operating income: $19.87M, up from $13.78M YoY.

• Net income for 9M 2025: $12.28M, down from $14.39M YoY; basic EPS: $0.62 vs. $0.72 YoY.

• Cash and equivalents at period end: $20.49M; total assets: $164.1M; equity: $110.46M.

• Gross margin for 9M 2025: 27.5%; operating margin: 17.3%.

• R&D expenses: $3.61M (3.14% of sales), up slightly YoY.

Outlook and guidance

• Board approved a plan for a year-end cash dividend, subject to confirmation of distributable profits after FY close.

• Focus remains on expanding premium skincare market share and targeting global top brands.